ClinicalTrials.gg
RecruitingNCT07070440Updated Aug 31, 2026

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

A Phase 1/2 interventional study of DZD6008 and Pemetrexed in Non Small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Dizal Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals — 6 open to participants now, 9 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Dizal Pharmaceuticals.

Planned enrollment
6th of 12
180 · median 160
Started
2025
with 3 others
Phase 1/2
4 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals, this one is the 6th largest by planned enrollment, is one of 4 that started in 2025, is one of 4 in phase 1/2, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals, or all of them as a file.
02

Study summary

This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Age ≥18 years old.
  3. Locally advanced or non-squamous non-small cell lung cancer by histopathology or cytology, not suitable for other radical treatment.
  4. Documentation of EGFR sensitizing mutation confirmed by local laboratory.
  5. Provide sufficient tumor tissue samples and plasma samples for retrospective analysis of EGFR mutations by central laboratory.
  6. Failure of prior 3 generations EGFR TKI or treatment naive.
  7. status score 0-1, ≥12 weeks.
  8. No central nervous system symptoms during screening, no need for or dehydration diuretic treatment for at least 4 weeks before the first dosing. If the patient with has received radiotherapy or surgery, there is a of ≥2 weeks before the first use of DZD6008 and ensure that the AE related to radiotherapy or surgery has recovered to ≤ 1 grade.
  9. Presence of defined by 1.1.
  10. Sufficient bone marrow or other organ reserve before first dosing.

Exclusion criteria

Exclusion criteria

  1. Histology mixed with small cell lung cancer (SCLC) or with SCLC transformation.
  2. Received the following treatments or had the following lifestyle habits, etc.:

    • Received immunotherapy or other antibody treatments (including EGFR-targeted antibodies, bispecific antibodies or antibody-drug conjugates, etc.) within 4 weeks before the first study drug administration.
    • Received any cytotoxic chemotherapy, study drugs or other anti-cancer drugs (excluding macromolecule drugs) within 14 days before the first study drug administration.
    • Received limited-range radiotherapy to relieve the disease within 7 days before the first study drug administration, or received more than 30% of the bone marrow radiotherapy or received wide-range radiotherapy within 28 days before the first medication.
    • 2 weeks (for inhibitors) or 3 weeks (for CYP3A4 inducers) before the first study drug administration, are taking or cannot stop taking known cytochrome P450 (CYP) 3A4 strong inhibitors or inducers (including herbal supplements, such as St. John's wort).
    • 2 weeks before the first study drug administration, are taking or cannot stop taking known CYP3A4 sensitive substrate drugs (with a narrow therapeutic window).
    • Taking or being unable to stop taking drugs known to be proton pump inhibitors within 1 week before the first study drug administration.
    • Major invasive surgery has been performed within 4 weeks before the first study drug administration or is planned during treatment.
  3. Presence of AEs of >1 grade (except any degree of alopecia) caused by previous treatment (such as chemotherapy, radiotherapy).
  4. Tumor-related spinal cord compression or meningeal .
  5. History of malignant tumor within 2 years (except for basal cell carcinoma of the skin or cervical cancer in situ that has been adequately treated; other tumors that have been tumor-free for more than 2 years and are expected to survive for more than 2 years, which needs to be discussed with Dizal clinical research physicians).
  6. Presence of severe or uncontrollable systemic diseases, including poorly controlled hypertension, bleeding diseases.
  7. Presence of persistent or active infections, including but not limited to , and infection (HIV).
  8. Any of the following heart-related diseases or abnormalities:

    • (QTc) >470 msec after calibration of 12-lead at rest during the screening period.
    • Any serious abnormalities of heart rate, conduction or pattern shown on the ECG at rest, such as complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec.
    • Any disease or condition that can cause QTcF prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or family members with a history of sudden death under the age of 40.
    • Severe cardiovascular diseases such as myocardial infarction, unstable angina or congestive heart failure, cerebrovascular accident (such as history of stroke or intracranial hemorrhage) within 6 months before the first dose.
    • History of deep vein thrombosis or pulmonary embolism within 4 weeks before the first dose (excluding non-obstructive catheter-related thrombosis).
  9. Patient history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring hormone treatment, or any clinically active ILD, immunotherapy-related pneumonitis.
  10. nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing medication, or previous intestinal resection that prevents adequate absorption of study medication.
  11. within 4 weeks before the first dose.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    DZD6008+pemetrexed/carboplatin

    DZD6008 was administered at 40/60/90 mg Once Daily (QD). Pemetrexed 500 mg/m2, once every 3 weeks, intravenous infusion. Carboplatin AUC 5 mg/mL/min, once every 3 weeks, intravenous infusion

    Drug: DZD6008 · Drug: Pemetrexed · Drug: Carboplatin

  • Experimental
    DZD6008+docetaxel

    DZD6008 was administered at 40/60/90 mg QD. Docetaxel 75 mg/m2, once every 3 weeks, intravenous infusion

    Drug: DZD6008 · Drug: Docetaxel

Interventions

  • DZD6008 was administered orally at 40/60/90 mg QD.

  • Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.

  • Carboplatin AUC 5 mg/mL/min, every 3 weeks, intravenous infusion.

  • Docetaxel 75 mg/m2, every 3 weeks, intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Number of participants with Dose-limiting Toxicities (DLTs)

    To assess safety and tolerability

    Time frame: 21 days after the first dosing

  2. Number of participants with Adverse events (AEs)/Serious adverse events (SAEs)

    To assess safety and tolerability

    Time frame: Through the study completion, an average of around 1 year.

  3. Objective Response Rate (ORR) as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    To assess anti-tumor activity

    Time frame: Through the study completion, an average of around 1 year.

Secondary outcomes

  1. Duration of Response(DoR)

    DoR is defined as the time from the date of the first documented response (subsequently confirmed) according to RECIST 1.1 to the date of objective disease progression or death, whichever occurred first.

    Time frame: Through the study completion, an average of around 1 year.]

  2. Disease Control Rate (DCR)

    DCR is defined as the proportion of subjects with response defined as complete response, partial response, and stable disease according to RECIST 1.1 by the investigator.

    Time frame: Through the study completion, an average of around 1 year.

  3. Progression Free survival (PFS)

    PFS is defined as the time from the first dose of the subject to objective disease progression based on RECIST 1.1 or death due to any cause (whichever occurs first).

    Time frame: Through the study completion, an average of around 1 year.

  4. Maximum Plasma Concentration (Cmax) of DZD6008

    Cmax = Maximum concentration

    Time frame: Plasma samples were collected at cycle 1, 2, 3, 5, 7, and 9, or cycle 1, 3, 5 and subsequent odd number cycles (cycle number adaptive to be consistent with tumor assessment), each cycle is 21 days

  5. Area Under the Plasma Concentration-time Curve from Zero to the Last Measurable Concentration (AUC0-t) of DZD6008

    AUC0-t= Area Under the Plasma Concentration-time Curve from Zero to the Last Measurable Concentration

    Time frame: Plasma samples were collected at cycle 1, 2, 3, 5, 7, and 9, or cycle 1, 3, 5 and subsequent odd number cycles (cycle number adaptive to be consistent with tumor assessment), each cycle is 21 days

  6. Maximum Plasma Concentration (Cmax) of docetaxel

    Cmax = Maximum concentration

    Time frame: Plasma samples were collected on at cycle 1 and 2, each cycle is 21 days

  7. Area Under the Plasma Concentration-time Curve from Zero to the Last Measurable Concentration (AUC0-t)of docetaxel

    AUC0-t = Area Under the Plasma Concentration-time Curve from Zero to the Last Measurable Concentration

    Time frame: Plasma samples were collected at cycles 1 and 2, each cycle is 21 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 23 months is below that.

Counting every sponsor, half of 435 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jul 17, 2025
StartActual
Jul 16, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07070440
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Jul 16, 2025
Primary completion
Jun 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Yuanli Dong
Contact
yuanli.dong@dizalpharma.com
+86 21 61095854
Lu
principal investigator · Shanghai Chest Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion